This review evaluated deferasirox in the treatment of iron overload associated with regular blood transfusions in chronic anaemia. It found that, in the short term, there was no evidence available to indicate a clinical difference between any of the chelators in removal of iron from the blood and liver. These conclusions appear reliable considering the limitations of the available evidence.
Study selection
Randomised controlled trials (RCTs) of patients with chronic anaemia requiring regular blood transfusions, that compared deferasirox with placebo, deferoxamine or deferiprone, or that compared combination therapy (deferoxamine plus deferiprone) with deferoxamine or deferiprone, were eligible for inclusion. Outcomes eligible for inclusion were absolute and relative change in serum ferritin, absolute and relative change in liver iron concentration, success rate, cardiac iron, quality of life, adverse effects and quality-adjusted life-year gained.
The duration of the included trials varied between five days and two years (the majority were approximately 12 months) and outcome measures varied across trials. Most trials included patients with beta-thalassaemia major or thalassaemia and their ages ranged from two to 54 years. The proportion of men and women were balanced across trials, but there were differences in baseline liver iron concentration and serum ferritin. Deferasirox doses varied across trials.
Studies were selected independently by at least two reviewers. Disagreements were resolved by discussion and if necessary another reviewer was consulted.
Assessment of study quality
Methodological quality was assessed using criteria based on the Centre for Review and Dissemination, Report 4.
Three reviewers independently assessed study quality and disagreements were resolved through discussion.
Data extraction
Data were extracted by one reviewer and checked by another. Where meta-analysis could be performed, means and standard deviations (SDs) were calculated. Authors were contacted for additional information if necessary.
Methods of synthesis
Means and standard deviations were pooled in a fixed-effect model if there was little statistical heterogeneity (this was only applicable to the outcome of serum ferritin). Otherwise trials were pooled using a DerSimonian and Laird randomeffects model. Statistical heterogeneity was assessed using χ 2 and I 2 . If these indicated heterogeneity, potential influences were investigated (planned a priori for age and disease). For outcomes with excessive clinical heterogeneity or poor methodological quality, trials were presented in a narrative synthesis.
Results of the review
Fourteen RCTs were included in the review (n=1,480 patients, range 13 to 586). One RCT was a double-blind parallel placebo controlled trial (n=65 patients).
Eight RCTs were open-label parallel trials (n=1,055 patients). One RCT was a crossover trial (n=20 patients). The remaining four RCTs were parallel (n=71 patients), parallel single-blind (n=144 patients), and two were parallel three-armed (n=125 patients) trials.
Overall trial quality was described as poor. Four RCTs described the method of randomisation, three described allocation concealment, two adequately addressed blinding of assessors, four performed intention-to-treat analyses (but this may have been inappropriate in one RCT), baseline characteristics were provided in eight RCTs, and comparability achieved in six. All trials provided number of patients randomised, eligibility criteria, and reported outcomes for at least 80% of those originally randomised.
Serum ferritin was significantly improved with combination therapy compared with deferoxamine at 12 months (WMD -0.71mg/L, 95% CI: -1.01 to -0.41; three RCTs) with no associated heterogeneity. There was no significant difference in serum ferritin with combination therapy compared with deferoxamine at six months (two RCTs), although this was associated with significant heterogeneity. There was no significant difference in serum ferritin at six months (two RCTs) or 12 months (three RCTs) with deferiprone compared with deferoxamine, although these analyses were also associated with significant heterogeneity.
Two trials suggested that 20mg/kg/day deferasirox was as effective as deferoxamine in terms of reduction of liver iron concentration.
Adverse events were also reported.
Cost information
The economic model suggested that deferasirox may be cost-effective (cost per quality-adjusted life-year less than £30,000 per year) for beta-thalassaemia major patients or sickle cell disease patients compared with deferoxamine. However this was dependent on the age of the patient and the use of balloon infusers to administer deferoxamine. Deferasirox was unlikely to be cost-effective compared with deferiprone.
Authors' conclusions
In the short term there was no evidence available to indicate a clinical difference between any of the three chelators in terms of removing iron from the blood and liver in patients with chronic anaemia.
CRD commentary
The research question was supported by clear inclusion criteria for participants, intervention, outcomes and study design. Only English language papers were sought, so language bias could not be ruled out. The review process was performed by at least two reviewers, reducing the possibility of reviewer error and bias.
Validity was assessed using an appropriate tool and trial quality was taken into consideration in the analysis. Metaanalysis appeared appropriate where performed and heterogeneity was investigated. Narrative synthesis appeared reasonable considering the evident clinical heterogeneity between trials. The authors discussed the limitations in terms of lack of generalisability to long-term outcomes and stated that they consider the analyses to be exploratory.
The authors' conclusions appear to be reliable considering the limitations of the available evidence.
One of the authors disclosed financial links with the pharmaceutical company Novartis (manufacturers of deferoxamine and deferasirox evaluated in the review).
